BioCentury
ARTICLE | Clinical News

ABT-894: Phase II data

June 23, 2008 7:00 AM UTC

In a double-blind, U.S. Phase II trial in about 200 patients, ABT-894 met the primary endpoint of a significant improvement vs. placebo in CAARS-Inv Total Score. The compound also showed comparable ef...